secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2023-12-27T23:59:59+00:00
Accession:  0001104659-23-129751
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA places clinical hold on Iovance's LN-145 NSCLC trial after fatal adverse event
--------------------------------------------------------------------------------

- FDA placed clinical hold on IOV-LUN-202 on Dec 22, 2023, after a Grade 5 fatal SAE potentially linked to preconditioning.
- Enrollment paused; previously treated patients monitored; those with tumor resection continue with risk mitigations.
- No impact on other Iovance trials or lifileucel BLA; PDUFA date remains Feb 24, 2024.
- Updated Nov 2023 data: 71% of confirmed responders had duration of response >6 months.
- Iovance will work with FDA to resume enrollment safely.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923129751/0001104659-23-129751-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923129751/tm2333764d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-129751

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer